• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    2U And 3 Other Stocks Under $4 Insiders Are Buying

    12/15/23 9:00:10 AM ET
    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Telecommunications Equipment
    Telecommunications
    Medical/Dental Instruments
    Health Care
    Get the next $CXDO alert in real time by email

    The Dow Jones index closed higher by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Delcath Systems

    • The Trade: Delcath Systems, Inc. (NASDAQ:DCTH) Chief Medical Officer Vojo Vukovic acquired a total of 40,000 shares an average price of $3.00. To acquire these shares, it cost around $120,000.
    • What’s Happening: On Nov. 13, Delcath Systems posted downbeat quarterly results.
    • What Delcath Systems Does: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers.

    2U

    • The Trade: 2U, Inc. (NASDAQ:TWOU) Chief Product Officer Aaron McCullough acquired a total of 51,565 shares at an average price of $0.99. To acquire these shares, it cost around $50,895.
    • What’s Happening: 2U, last month, reported mixed third-quarter financial results and cut 2023 revenue guidance.
    • What 2U Does: 2U Inc provides educational technology services for nonprofit colleges and universities.

    Check This Out: Top 4 Energy Stocks Which Could Rescue Your Portfolio This Month

    Crexendo

    • The Trade: Crexendo, Inc. (NASDAQ:CXDO) Chief Revenue Officer Jon Brinton acquired a total of 2,000 shares at an average price of $3.03. The insider spent around 6,050 to buy those shares.
    • What’s Happening: On Nov. 9, Crexendo posted better-than-expected third-quarter earnings.
    • What Crexendo Does: Crexendo Inc is a provider of cloud communications, UCaaS, call center, collaboration services, and other cloud business services.

    Elys Game Technology

    • The Trade: Elys Game Technology, Corp. (OTC:ELYS) 10% owner Gold Street Capital Corp acquired a total of 807,530 shares at an average price of $0.16. The insider spent around $129,205 to buy those shares.
    • What’s Happening: On Nov. 7, Elys Game Technology announced a market access agreement with Caesars Entertainment that unlocks immediate access to the lucrative Colorado sports betting market.
    • What Elys Game Technology Does: Elys Game Technology Corp is a fastest growing and technologically advanced Sports Betting and virtual sports betting products provider in the regulated business to business and business to consumer markets.

     

    Don’t forget to check out our premarket coverage here

    Get the next $CXDO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CXDO
    $DCTH
    $ELYS
    $TWOU

    CompanyDatePrice TargetRatingAnalyst
    Crexendo Inc.
    $CXDO
    7/1/2025$8.00Buy
    Needham
    Crexendo Inc.
    $CXDO
    4/7/2025$8.00Buy
    Craig Hallum
    Crexendo Inc.
    $CXDO
    1/21/2025$7.00Buy
    D. Boral Capital
    Delcath Systems Inc.
    $DCTH
    6/28/2024$18.00Buy
    Craig Hallum
    Delcath Systems Inc.
    $DCTH
    5/14/2024$25.00Overweight
    Stephens
    Crexendo Inc.
    $CXDO
    5/8/2024$6.75 → $5.75Neutral → Buy
    B. Riley Securities
    2U Inc.
    $TWOU
    2/13/2024Buy → Hold
    Needham
    Crexendo Inc.
    $CXDO
    1/31/2024$4.50 → $6.75Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by GM INTERVENTIONAL ONCOLOGY Muir Kevin

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    2/18/26 9:30:13 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by GEN'L COUNSEL, CCO & SECY Hoffman David L.

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    2/18/26 9:30:14 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by CHIEF OPERATING OFFICER Rook Martha S.

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    2/18/26 9:30:07 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15c A replay of the w

    2/12/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (

    1/27/26 8:05:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025. The grants, in the form of Restricted Stock Units (RSUs), totaled 36,250 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The RSUs were granted on January 2, 2026 and one-third of the RSUs will vest on the first anniver

    1/21/26 4:01:00 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    SEC Filings

    View All

    Delcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    1/12/26 4:41:41 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Crexendo Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Crexendo, Inc. (0001075736) (Filer)

    12/4/25 7:23:06 PM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    SEC Form 8-K filed by Delcath Systems Inc.

    8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    11/20/25 4:45:09 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Crexendo with a new price target

    Needham initiated coverage of Crexendo with a rating of Buy and set a new price target of $8.00

    7/1/25 8:17:53 AM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    Craig Hallum initiated coverage on Crexendo with a new price target

    Craig Hallum initiated coverage of Crexendo with a rating of Buy and set a new price target of $8.00

    4/7/25 7:59:05 AM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    D. Boral Capital initiated coverage on Crexendo with a new price target

    D. Boral Capital initiated coverage of Crexendo with a rating of Buy and set a new price target of $7.00

    1/21/25 9:07:40 AM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sylvester John Richard bought $38,992 worth of shares (4,386 units at $8.89), increasing direct ownership by 42% to 14,936 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    11/25/25 4:15:07 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $98,049 worth of shares (11,500 units at $8.53), increasing direct ownership by 4% to 330,834 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    11/13/25 11:53:28 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Chief Revenue Officer Brinton Jon bought $3,010 worth of shares (1,000 units at $3.01), increasing direct ownership by 0.99% to 101,553 units (SEC Form 4)

    4 - Crexendo, Inc. (0001075736) (Issuer)

    6/17/24 6:59:15 PM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Financials

    Live finance-specific insights

    View All

    Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15c A replay of the w

    2/12/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Total revenue of $20.6 million, compared with $11.2 million in the third quarter of 2024 HEPZATO KIT™ revenue of $19.3 million, compared to $10.0 million in the third quarter of 2024 CHEMOSAT® revenue of $1.3 million, compared to $1.2 million in the third quarter of 2024 Gross margins of 87%, compared to 85% in the third quarte

    11/4/25 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Delcath Systems to Host Third Quarter 2025 Earnings Call

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, November 4, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1735083&tp_key=a3bb91787b A replay of the webinar will be a

    10/21/25 8:30:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 9:46:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

    SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 7:02:01 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $CXDO
    $DCTH
    $ELYS
    $TWOU
    Leadership Updates

    Live Leadership Updates

    View All

    Beta Bionics Announces Board Appointment of Gerard Michel

    IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

    3/27/25 4:45:06 PM ET
    $BBNX
    $DCTH
    Medical/Dental Instruments
    Health Care

    Crexendo(R) Honored for Outstanding Platform Usability and Exceptional Customer Relationships in G2's Summer 2024 Reports

    The company retained its position as a top trending provider for VoIP, UCaaS, and CCaaS, by real verified customers. PHOENIX, AZ / ACCESSWIRE / July 10, 2024 / Crexendo®, Inc. (NASDAQ:CXDO), an award-winning premier provider of cloud communication platforms and services, video collaboration and managed IT services designed to provide enterprise-class cloud solutions to any size business, today announced that it has been recognized for outstanding platform usability and exceptional customer satisfaction in G2's Summer 2024 Reports for VoIP, UCaaS, and Customer Communications Management. G2.com is the leading business software review website where users research and select solutions reviewed a

    7/10/24 9:00:00 AM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    Crexendo Names Tim Wilbourn as Senior Vice President of Support and Customer Success

    PHOENIX, AZ / ACCESSWIRE / June 19, 2024 / Crexendo, Inc. (NASDAQ:CXDO), an award-winning premier provider of cloud communication platforms and services, video collaboration, and managed IT services designed to provide enterprise-class cloud solutions to any size business, is excited to announce the appointment of Tim Wilbourn as the new Senior Vice President of Support and Customer Success. Mr. Wilbourn brings over a decade of expertise in customer experience and strategic leadership within the Software as a Service (SaaS) and Unified Communications as a Service (UCaaS) sectors.Over the course of 11 years at Ring Central, Tim established himself as a formidable leader in shaping customer en

    6/19/24 9:00:00 AM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications